Articles By Jack Cush, MD
C5a and Neutrophils as Early Mediators in Inflammatory Arthritis
Researchers from the Massachusetts General Hospital (MGH) have studied the initial steps in an animal model of inflammatory arthritis and found that complement C5a is critical to neutrophils migration into joints.
Read Article
Ties to Pharma Influences Clinical Trial Results
A study published in The BMJ shows that financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results; thereby questioning the bias in these objective trials.
Read Article
FDA Issues Draft Guidance on Biosimilar Interchangeability
Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?
Read Article
The RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Read Article
EULAR Revised Recommendations for Fibromyalgia
The European League Against Rheumatism (EULAR) recommendations for fibromyalgia (FM) management were published in 2007 and largely had recommendations based on expert opinion’. These guidelines were updated in May of 2015 after a systematic reviews and meta-analyses of the data.
Read Article
Consensus Guidelines for Juvenile Dermatomyositis Management
SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).
Read Article
Dietary Intake Triggers Inflammation
IL-1β, along with pancreatic insulin, helps regulate blood sugar levels, as well as chronic inflammation.
Read Article
Patient and Provider Education Fails to Improve Osteoarthritis Outcomes
A randomized trial of 537 knee osteoarthritis (OA) patients in the Duke Healthcare system has shown that patient- and provider interventions were no better than the usual standard of care.
Read Article
Rituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis
Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.
Read Article
The RheumNow Week in Review – 13 January 2017
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Read Article
